References
- Abrams P, Andersson KE, Buccafusco JJ, Chapple C, et al. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148, 565–578.
- Khattar S, Bora RS, Priyadarsiny P, Gupta S, et al. High-level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells. Biotechnol Lett 2006, 28, 121–129.
- Osborne HB, Brann MR. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assay in mammalian cells. Eur J Pharmacol 1996, 295, 93–102.
- Hegde SS. Muscarinic receptors in the bladder: From basic research to therapeutics. Br J Pharmacol 2006, 147, S80–S87.
- Felder CC. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J 1995, 9, 619–625.
- Ohtake A, Saitoh C, Yuyama H, Ukai M, et al. Pharmacological characterization of a new Antimuscarinic agent, Solifenacin Succinate, in comparison with other Antimuscarinic agents. Biol Pham Bull 2007, 30, 54–58.
- Andersson KE. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl 2002, 1, 23–28.
- Ehlert FJ. Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinar bladder smooth muscle. Life Sci 2003, 74, 355–366.
- Lowry OH, Rosenburg NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951, 193, 265–275.
- Moriya H, Takagi Y, Nakanishi T, Hayashi M, et al. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999, 64, 2351–2358.
- Denning GM, Clark RA, Welsh MJ. cAMP and inositol 1,4,5-triphosphate increase Ca+2 in HT-29 cells by activating different Ca+2 influx pathways. Am J Physiol 1994, 267, C776–C783.
- Felder CC, Poulter MO, Wess J. Muscarinic receptor operated Ca+2 influx in transfected fibroblast cells is independent of inositol phosphates and release of intracellular calcium. Proc Natl Acad Sci USA 1992, 89, 509–513.
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor, which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973, 22, 3099–3108.
- Grynkiewiez G, Poenie M., Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260, 3440–3460.
- Tsien RY, Rink TJ, Poenie M. Measurement of cytosolic free Ca2+ in individual small cells using fluorescence microscopy with dual excitation wavelengths. Cell Calcium 1985, 6, 145–157.
- Watson N, Daniels DV, Ford APDW, Eglen RM, Hegde SS. Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells. Br J Pharmacol 1999, 127, 590–596.
- Kassack MU, Hofgen B, Lehmann J, Eckstein N, et al. Functional screening of G-protein coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. J Biomol Screen 2002, 7, 233–246.